

EYLEA® (aflibercept) 8 mg real-world evidence 12-month outcomes in treatment-naïve patients with nAMD

Moorfields Eye Hospital, Bedford Hospitals NHS Trust

These data are from real patients. Individual results may vary.

Study design:

Retrospective study explored the visual acuity, central retinal thickness and changes in fluid status in treatment-naïve patients with nAMD (N=26 eyes) who received EYLEA 8 mg at Moorfields Eye Clinic.


All patients received three monthly doses of EYLEA 8 mg, followed by a T&E protocol per the UK licensed posology.

Patient demographics

Eyes, N	26
Mean age, years	82.5
Female, %	69.2


Fast drying with 3 loading doses of EYLEA 8 mg

Fluid status over time



Of the patients who had received six doses of EYLEA 8 mg, **64.7%** (N=11/17) achieved **fluid-free status**

Change in CRT over time



Median
-198.0 µm

Mean
-205.2 µm

Change in CRT from baseline (N=26) after six injections of EYLEA 8 mg (N=17)†

*One eye was missing data because of treatment discontinuation. †Not all patients had received more than four doses of EYLEA 8 mg at the time of this audit (January 2026) and therefore patient numbers differ from baseline.

Abbreviations:

CRT, central retinal thickness; IRF, intraretinal fluid; nAMD, neovascular age-related macular degeneration; SRF, subretinal fluid; T&E, treat-and-extend.

Reference:

Bayer UK Data on File_PP-EYL_8mg-GB-0857_January 2026.

May 2026 | PP-EYL_8mg-GB-1042

© Bayer plc. ® Registered trademark of BAYER AG, Germany.


Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.

Either click [here](#) or scan the QR code for prescribing information and adverse event reporting information. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.



Interval extension with EYLEA 8 mg


Last completed treatment interval at the seventh injection visit (after six injections)



Disease biomarker improvements with EYLEA 8 mg

BIOMARKERS	Proportion of patients with PED		Proportion of patients with SHRM		Proportion of patients with Macular haemorrhage	
	Baseline (N=26)	92.3%	Baseline (N=26)	73.1%	Baseline (N=26)	19.2%
	After six doses (N=17)	47.1%	After six doses (N=17)	0%	After six doses (N=17)	5.9%

Vision gains with EYLEA 8 mg



No adverse events were reported in this audit with EYLEA 8 mg

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.

Values may not add up to 100% because of rounding.

*Not all patients had received more than four doses of EYLEA 8 mg at the time of this audit (January 2026) and therefore patient numbers differ from baseline.

†Not all patients had available data at the seventh injection. †One eye was missing data because of treatment discontinuation.

‡Vision not reported for one patient.

Abbreviations:

ETDRS, Early Treatment Diabetic Retinopathy Study; PED, pigment epithelial detachment; qX, every X weeks; SHRM, subretinal hyperreflective material; SmPC, Summary of Product Characteristics; VA, visual acuity.

Reference:

Bayer UK Data on File_PP-EYL_8mg-GB-0857_January 2026

May 2026 | PP-EYL_8mg-GB-1042

© Bayer plc. ® Registered trademark of BAYER AG, Germany.

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.

Either click [here](#) or scan the QR code for prescribing information and adverse event reporting information. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

